Subject(s)
Fetal Blood , Fetomaternal Transfusion , Female , Fetomaternal Transfusion/therapy , Fetus , Humans , PregnancyABSTRACT
Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) vertical transmission is an open issue. Recent reports call into question in utero or peripartum viral transmission to the offspring. Few data are available on immunoglobulin G (IgG) and/or IgM in newborns. Insufficient evidence is available regarding passive immunity in neonates born from SARS-CoV-2 infected women. We report a case of a neonate showing the presence of blood specific IgG and the absence of IgM and negative nasopharyngeal swab. He was born from an asymptomatic SARS-CoV-2-infected mother with positive IgG and IgM. The transplacental passage of specific IgG antibodies from the affected mother to the unaffected fetus highlights neonatal passive immunity.
Subject(s)
Antibodies, Viral/blood , COVID-19/transmission , Immunity, Maternally-Acquired/immunology , Infectious Disease Transmission, Vertical , SARS-CoV-2/immunology , Adult , COVID-19/diagnosis , Female , Humans , Immunoglobulin G/blood , Immunoglobulin M/blood , Infant, Newborn , Male , Pregnancy , Pregnancy Complications, Infectious/virologySubject(s)
Lymphedema/physiopathology , Pregnancy Complications/physiopathology , Pregnancy Outcome , Adult , Female , Humans , Infant, Newborn , PregnancyABSTRACT
BACKGROUND: Sibutramine is a drug that is used in the treatment of obesity. There are currently no epidemiological studies relating to sibutramine exposure in pregnancy. The objective of our study was to determine whether sibutramine exposure during pregnancy constitutes a risk factor to the mother and developing fetus. METHODS: Fifty-two pregnant women who were exposed to sibutramine in the first trimester of pregnancy, when they were unaware of being pregnant, contacted our Teratology Information Service. We recorded the prospective outcomes of this case series between May 2001 and September 2004 with a complete neonatal follow-up up to 1 month after delivery. RESULTS: Seven cases of hypertensive complications were observed during pregnancies. No cases of congenital anomalies in neonates were observed. CONCLUSION: Although many more cases are necessary to demonstrate that sibutramine is not teratogenic in pregnancy, our experience improves the counseling of pregnancies occurring involuntarily during sibutramine therapy.
Subject(s)
Abnormalities, Drug-Induced , Appetite Depressants/adverse effects , Cyclobutanes/adverse effects , Maternal Exposure/adverse effects , Obesity/drug therapy , Pregnancy Complications/drug therapy , Pregnancy Outcome , Abnormalities, Drug-Induced/epidemiology , Adult , Appetite Depressants/therapeutic use , Body Mass Index , Counseling , Cyclobutanes/therapeutic use , Drug Information Services , Female , Humans , Hypertension/complications , Infant, Newborn , Italy/epidemiology , Obesity/complications , Pregnancy , Pregnancy Outcome/epidemiology , Pregnancy Trimester, First/drug effects , Prospective Studies , Risk Factors , TeratologyABSTRACT
PURPOSE: To observe pregnancies exposed to latanoprost, a prostaglandin analog administered in the treatment of glaucoma. Its prescription is limited in pregnancy, because reproduction studies in animals report a high incidence of abortion and human investigations are not adequate. As a consequence it is classified as category C drug according to the United States Food and Drug Administration's use-in-pregnancy ratings. DESIGN: Observational study. METHODS: We collected data, referred to our Teratology Information Service, relative to latanoprost exposure in pregnancy. We followed by phone interviews women treated with latanoprost during the first trimester, and we evaluated whether there had been any adverse effects on the fetus. RESULTS: Eleven cases of latanoprost exposure in pregnancy were referred to our Teratology Information Service. One case was lost to follow-up, and one case was complicated by miscarriage. Nine cases had a complete follow-up without congenital anomalies. CONCLUSIONS: Our series is too small to perform statistical significance; however, we found no evidence of adverse effects of latanoprost on pregnancy or neonatal outcomes.
